Michael Reardon (Houston, USA) talks to BLearning Cardio about the ADAPT tissue technology (Admedus), and the increasing importance of durability as TAVI moves to younger and lower risk patients.

Reardon notes that “we would like to have technology that does even better than the surgical valves”, and believes better durability will be the result of “tissue science and valve design”. He also discusses the use of ADAPT technology in more than 20,000 paediatric cases, which Reardon claims “worked very well” in part due to ADAPT’s “completely acellular tissue”. This, says Reardon, “leads us to believe that the tissue science behind ADAPT is going to be a game-changer”.

Reardon concludes by outlining his view on the future of TAVI, which he says will rest on increased durability and the ability to anatomically align valves. Going forward, he believes a valve that is “simple, reusable and reliable” will be key.